# Haploid Allogeneic Transplant Using the CliniMACS System

> **NCT00185679** · PHASE2 · TERMINATED · sponsor: **Ginna Laport** · enrollment: 13 (actual)

## Conditions studied

- Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors
- Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase
- Myelodysplastic Syndrome (MDS) - High and Intermediate Risk
- Non-Hodgkin's Lymphoma (NHL)
- Chronic Lymphocytic Leukemia (CLL) - Refractory

## Interventions

- **DEVICE:** CliniMACS System

## Key facts

- **NCT ID:** NCT00185679
- **Lead sponsor:** Ginna Laport
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-11
- **Primary completion:** 2009-10
- **Final completion:** 2010-02
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** This study was superseded by the subsequent study IRB-15919 (NCT01050764)
- **Last updated:** 2015-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00185679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00185679, "Haploid Allogeneic Transplant Using the CliniMACS System". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00185679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*